11.07.2015 Views

Sedation in ICU Patients

Sedation in ICU Patients

Sedation in ICU Patients

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

<strong>Sedation</strong> <strong>in</strong> <strong>ICU</strong> <strong>Patients</strong>• Old agents for sedation– Benzodiazep<strong>in</strong>es– Opioids– Propofol• Problems with delerium• New agents– Dexmedetomid<strong>in</strong>e– Ketam<strong>in</strong>e– Fospropofol


Traditional <strong>ICU</strong> <strong>Sedation</strong>• Opioids• Benzodiazep<strong>in</strong>es– Midazolam– Lorazepam– Diazepam• Propofol


GABA Receptor


Lorazepam Dose and Probability ofDeliriumPandharipande. Anesthesiology 2006


Effect of Midazolam on Delirium


Avoid<strong>in</strong>g GABA Agonist relatedDelirium• Don’t sedate• Target appropriate sedation levels• Daily <strong>in</strong>terruption of sedation– Drug holidays


Effect of Daily Interruption of<strong>Sedation</strong>P < 0.0001Kress, NEJM, 2000


Effect of Daily Interruption of<strong>Sedation</strong>P = 0.02Kress, NEJM, 2000


Delirium: A never event?• Delirium proposed by CMS as a “Never Event”2008• “Never Events” are errors <strong>in</strong> medical care that areclearly identifiable, preventable, and serious <strong>in</strong>consequences and <strong>in</strong>dicate a problem <strong>in</strong> the safetyof a healthcare facility• Medicare List of Unreimbursed PreventableConditions


Delirium• Incidence <strong>in</strong> Surgical and Thoracic Intensive CareUnits– 11% to 80%• Each additional day of delirium– Increases the risk of prolonged hospitalization by 20%– Increases the likelihood of a poor functional status at 3and 6 months• Delirium is associated with $15k to $25k higherhospital costs• Delirious patients have a 5X <strong>in</strong>crease <strong>in</strong> selfextubation


Modifiable Risk Factors• Lack of social <strong>in</strong>teraction• Frequent nurs<strong>in</strong>g care• Medications• Pa<strong>in</strong>• Sleep disturbance


Treatment StrategiesMaldonado. Crit Care Cl<strong>in</strong>. 2008


Reduction <strong>in</strong> Mortality with HaloperidolMilbrandt Crit Care Med 2005


Haloperidol Side Effects• Prolongation of QT <strong>in</strong>terval– Torsade de Po<strong>in</strong>tes ventricular tachycardia• Extrapyramidal side effects– Very rare with IV use of haloperidol• Neurolept malignant syndrome– Aga<strong>in</strong> very rare with IV use


Pharmacologic Profiles ofAntipsychoticsCasey. J Cl<strong>in</strong> Psych. 1997


Effect of Quetiap<strong>in</strong>e on Incidence andDuration of Delirium• 36 adult <strong>in</strong>tensive care unit patients withdelirium• Quetiap<strong>in</strong>e 50mg BID• Increased by 50mg every 12 hrs ifhaloperidol required• Reduced <strong>in</strong>cidence and duration ofdelirium.Devl<strong>in</strong>, Crit Care Med 2010


Effect of Quetiap<strong>in</strong>e on Incidence andDuration of DeliriumDevl<strong>in</strong>, Crit Care Med 2010


Risperidone and Delirium• Double-bl<strong>in</strong>d randomized trial• S<strong>in</strong>gle dose (1 mg) of risperidoneadm<strong>in</strong>istered after cardiac surgery– subl<strong>in</strong>gual• Reduced the <strong>in</strong>cidence of postoperativedelirium– 11.1% vs. 31.7%, P=.009– RR=0.35, 95% CI=0.16-0.77Prakanrattana, et al. Anaesth Intensive Care. 2007


Dexmedetomid<strong>in</strong>e• α2-receptor agonist• Properties similar to natural sleep– sedated but arousable• Analgesic properties• Side effects– Hypotension– Bradycardia– S<strong>in</strong>us arrest– No respiratory depression• Short distribution half-life (t½) - 6 m<strong>in</strong>utes• Term<strong>in</strong>al elim<strong>in</strong>ation half-life (t½) - 2 hours


MENDS• Maximiz<strong>in</strong>g Efficacy of Targeted <strong>Sedation</strong> andReduc<strong>in</strong>g Neurological Dysfunction Study• 106 adult mechanically ventilated medical andsurgical <strong>ICU</strong> patients• Titrated to RASS• Randomized to dexmedetomid<strong>in</strong>e or lorazepam• t1/2 of unconjugated lorazepam is 12 hours• Major metabolite, lorazepam glucuronide, t1/2about 18 hoursPandharipande, JAMA, 2007


MENDSPandharipande, JAMA, 2007


SEDCOM• Safety and Efficacy of Dexmedetomid<strong>in</strong>eCompared With Midazolam Study Group• Prospective, double-bl<strong>in</strong>d, randomized trial• 68 centers <strong>in</strong> 5 countries• 375 medical/surgical <strong>ICU</strong> patients• Expected mechanical ventilation for morethan 24 hoursRiker, JAMA, 2009


SEDCOM: Prevalence of DeliriumRiker, JAMA, 2009


SEDCOM: Time to ExtubationRiker, JAMA, 2009


SEDCOMRiker, JAMA, 2009


Dexmedetomid<strong>in</strong>e for <strong>Sedation</strong> afterCPB for Valve SurgeriesMaldonado, Psychosomatics, 2009


Fast Track Cardiac Surgery• Recovery room extubation• CABG +/- valve• Dexmedetomid<strong>in</strong>e vs propofol sedation• Retrospective• <strong>Patients</strong> were matched accord<strong>in</strong>g to surgerytype and left ventricular ejection fractionBarletta, Pharmacotherapy, 2009


Fast Track Cardiac SurgeryBarletta, Pharmacotherapy, 2009


Ketam<strong>in</strong>e for Intubation on the <strong>ICU</strong>?• Etomidate is the least cardiac depressant<strong>in</strong>duction agent– Known to cause adrenal suppression on<strong>in</strong>fusion• Ketam<strong>in</strong>e is sympathomimetic– Raises BP and heart rate– Can cause halluc<strong>in</strong>ations


Etomidate vs Ketam<strong>in</strong>e forIntubation• Emergency <strong>in</strong>tubation– 12EDs and 65 <strong>ICU</strong>s <strong>in</strong> France• 469 patients• No difference <strong>in</strong>:– SOFA scores– Probability of be<strong>in</strong>g on ventilation– Vasopressors requirementJabre, Lancet, 2009


Etomidate vs Ketam<strong>in</strong>e forIntubationKetam<strong>in</strong>eEtomidateP=0.36Jabre, Lancet, 2009


Adrenal Effects of Etomidate vsKetam<strong>in</strong>e16(11-15) 25(17-34)18(12-29) 33(25-41)19(14-30) 38(28-48)9 mcg/dL,10 mcg/dL,9 mcg/dLJabre, Lancet, 2009


Propofol• Risks– Not reliably amnestic, especially at low doses– No analgesia!– Hypotension– Respiratory depression– Propofol Infusion Syndrome• Cardiac failure, rhabdomyolysis, severe metabolic acidosis,and renal failure• Caution should be exercised at doses > 80 mcg/kg/m<strong>in</strong> formore than 48 hours• Problematic when used simultaneously with catecholam<strong>in</strong>esand/or steroids


Propofol• Formulated <strong>in</strong> 10% Intralipid– Egg phosphatid and soy lecith<strong>in</strong>– Emulsion which is miscible with aqueoussolutions– Lipid load (1.1 kcal/ml)– Hypertriglyceridemia– Medium for bacterial overgrowth


Fospropofol


Fospropofol• Pro-drug of propofol• Aqueous solubility• No lipid emulsion• Slower onset• Less hypotension and respiratory depressionfor procedures


FospropofolAlkal<strong>in</strong>ePhosphatasePropofol Formaldehyde Phosphate


Fospropofol Side Effects• Anal and genital– Itch<strong>in</strong>g– Burn<strong>in</strong>g– Paresthesia• Phosphate


Fospropofol• Formaldehyde metabolized to formate• Formate <strong>in</strong> high concentrations:– Acidosis– Ketonemia– Acetonuria– Respiratory compromise– Bl<strong>in</strong>dness

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!